HAEMONETICS CORP - Common Stock (HAE)

Q3 2019 13F Holders as of 30 Sep 2019

Type / Class
Equity / Common Stock
Shares outstanding
47,898,935
Total 13F shares
49,617,874
Share change
-1,286,051
Total reported value
$6,258,106,643
Put/Call ratio
213%
Price per share
$126.14
Number of holders
271
Value change
-$157,380,306
Number of buys
131
Number of sells
120

Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q3 2019

As of 30 Sep 2019, HAEMONETICS CORP - Common Stock (HAE) was held by 271 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 49,617,874 shares. The largest 10 holders included BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, Capital Research Global Investors, Neuberger Berman Group LLC, FMR LLC, Jackson Square Partners, LLC, STATE STREET CORP, and FRANKLIN RESOURCES INC. This page lists 271 institutional shareholders reporting positions in this security for the Q3 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.